Cargando…

TCR-Engineered, Customized, Antitumor T Cells for Cancer Immunotherapy: Advantages and Limitations

The clinical outcome of the traditional adoptive cancer immunotherapy approaches involving the administration of donor-derived immune effectors, expanded ex vivo, has not met expectations. This could be attributed, in part, to the lack of sufficient high-avidity antitumor T-cell precursors in most c...

Descripción completa

Detalles Bibliográficos
Autor principal:	Chhabra, Arvind
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	TheScientificWorldJOURNAL 2011
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720046/ https://www.ncbi.nlm.nih.gov/pubmed/21218269 http://dx.doi.org/10.1100/tsw.2011.10

Ejemplares similares

TCR engineered T cells for solid tumor immunotherapy
por: Zhang, Yikai, et al.
Publicado: (2022)

The Quest for the Best: How TCR Affinity, Avidity, and Functional Avidity Affect TCR-Engineered T-Cell Antitumor Responses
por: Campillo-Davo, Diana, et al.
Publicado: (2020)

Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets
por: Laletin, Vladimir, et al.
Publicado: (2023)

Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
por: Pang, Zhi, et al.
Publicado: (2023)

Trial Watch: Adoptive TCR-Engineered T-Cell Immunotherapy for Acute Myeloid Leukemia
por: Campillo-Davo, Diana, et al.
Publicado: (2021)

TCR-like antibodies in cancer immunotherapy
por: He, Qinghua, et al.
Publicado: (2019)

Autophagic flux restoration of senescent T cells improves antitumor activity of TCR‐engineered T cells
por: Zhang, Chaoting, et al.
Publicado: (2022)

Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons
por: Zhao, Qijie, et al.
Publicado: (2021)

TCR-NK Cells: A Novel Source for Adoptive Immunotherapy of Cancer
por: Karahan, Zeynep Sena, et al.
Publicado: (2023)

Beyond TCR Signaling: Emerging Functions of Lck in Cancer and Immunotherapy
por: Bommhardt, Ursula, et al.
Publicado: (2019)

The Enigmatic Nature of the TCR-pMHC Interaction: Implications for CAR-T and TCR-T Engineering
por: Shevyrev, D. V., et al.
Publicado: (2022)

Creatine in T Cell Antitumor Immunity and Cancer Immunotherapy
por: Li, Bo, et al.
Publicado: (2021)

TCR-T Immunotherapy: The Challenges and Solutions
por: Liu, Yating, et al.
Publicado: (2022)

NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma
por: Rapoport, Aaron P., et al.
Publicado: (2015)

Microorganisms in the Treatment of Cancer: Advantages and Limitations
por: Łukasiewicz, Klaudia, et al.
Publicado: (2018)

Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia
por: Zhou, Weijun, et al.
Publicado: (2022)

Evolution of CD8(+) T Cell Receptor (TCR) Engineered Therapies for the Treatment of Cancer
por: Sun, Yimo, et al.
Publicado: (2021)

Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy
por: Rath, Jan A., et al.
Publicado: (2020)

Harnessing Antitumor CD4(+) T Cells for Cancer Immunotherapy
por: Ben Khelil, Myriam, et al.
Publicado: (2022)

Emerging Strategies in TCR-Engineered T Cells
por: Wei, Fang, et al.
Publicado: (2022)

Transpulmonary thermodilution: advantages and limits
por: Monnet, Xavier, et al.
Publicado: (2017)

TCR diversity – a universal cancer immunotherapy biomarker?
por: McNeel, Douglas G.
Publicado: (2016)

Harnessing the antitumor potential of macrophages for cancer immunotherapy
por: Long, Kristen B, et al.
Publicado: (2013)

A Costimulatory CAR Improves TCR-based Cancer Immunotherapy
por: Omer, Bilal, et al.
Publicado: (2022)

Δ133p53α enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity
por: Legscha, Kevin Jan, et al.
Publicado: (2021)

Advantages and Limitations of Animal Schizophrenia Models
por: Białoń, Magdalena, et al.
Publicado: (2022)

The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients
por: Arnaud, Marion, et al.
Publicado: (2021)

Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy
por: Jazirehi, Ali R.
Publicado: (2021)

Advances in Engineering Cells for Cancer Immunotherapy
por: Xu, Xiao, et al.
Publicado: (2019)

Epigenetic modulation of antitumor immunity for improved cancer immunotherapy
por: Dai, Enyong, et al.
Publicado: (2021)

Limitations for TCR gene therapy by MHC-restricted fratricide and TCR-mediated hematopoietic stem cell toxicity
por: Schendel, Dolores J., et al.
Publicado: (2013)

Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8αβ-engineered human CD4(+) T cells
por: Rath, Jan A., et al.
Publicado: (2020)

Advantages and Limitations of Ultrasound as a Screening Test for Ovarian Cancer
por: Koutras, Antonios, et al.
Publicado: (2023)

Genetically engineered T cells for cancer immunotherapy
por: Li, Dan, et al.
Publicado: (2019)

Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
por: Dillard, Pierre, et al.
Publicado: (2021)

Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
por: Shafer, Paul, et al.
Publicado: (2022)

Inlays, Their Advantages and Limitations
por: Johnson, C. N.
Publicado: (1900)

FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance
por: Caratelli, Sara, et al.
Publicado: (2017)

Optimizing engineered TCR T cell therapy for synovial sarcoma
por: D'Angelo, Sandra, et al.
Publicado: (2015)

TCR-engineered T cells: A model of inducible TCR expression to dissect the interrelationship between two TCRs
por: Reuß, Simone, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ahnn652b33t78ksdarafnvulds